seen from United States
seen from Türkiye
seen from France
seen from United States
seen from Finland
seen from China
seen from United Kingdom
seen from China
seen from Georgia
seen from United States
seen from Türkiye
seen from Indonesia
seen from United States
seen from United States
seen from Germany
seen from Türkiye
seen from China
seen from Finland
seen from China
seen from Italy
Dabigatran
Patreon
Unsafe Interaction Between Pradaxa and Common Calcium Channel Blockers
Unsafe Interaction Between Pradaxa and Common Calcium Channel Blockers
An observational study published in 2020 found that people with A-Fib taking two common rate control calcium channel blockers along with the anticoagulant Pradaxa had higher bleeding rates (GI bleeding, minor bleeding, and minor GI bleeding). The study was an analysis of the potential drug-drug interaction between verapamil or diltiazem and DOACs. The term DOAC has replaced use of NOAC. The study…
View On WordPress
Dabigatran Etexilate Mesylate
Brand Name: Pradaxa
Common Dosage Forms:
Capsules: 75 mg and 150 mg.
FDA Indications/Dosages:
Indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation:
In patients with CrCL >30 mL/min: 150 twice a day.
In patients with CrCL 15-30 mL/min: 75 mg twice a day.
Converting from parenteral anticoagulants: Start 0-2 hours before the next dose of the parental anticoagulant is due.
Converting to a parental anticoagulant: Wait 12 hours (CrCL >30 mL/min) or 24 hours (CrCL 15-30 mL/min) after the last dose of PRADAXA before starting a parental anticoagulant.
Converting from warfarin: Stop warfarin and wait until the INR is below 2.0.
Converting to warfarin: Start warfarin before stopping PRADAXA based on the CrCL (>50 mL/min=3 days, 30-50 mL/min=2 days, 15-30 mL/min=1 day).
Monitor: RFT.
Pharmacology/Pharmacokinetics: Dabigatran and its metabolites are competitive, direct thrombin inhibitors. Thrombin is an important component of the coagulation cascade, converting fibrinogen into fibrin. Both free and clot-bound thrombin, and thrombin-induced platelet aggregation are inhibited. Oral bioavailability is low at 3% to 7% and is affected by the activity of P-glycoprotein. Dabigatran etexilate is converted after absorption into dabigatran. Protein-binding is relatively low at 35%. Elimination occurs primarily in the urine.
Drug Interactions: Rifampin and St. John’s Wort may decrease blood levels of dabigatran through induction of P-glycoprotein in the intestine and kidney. P-glycoprotein inhibitors (verapamil, dronedarone, ketoconazole, amiodarone, quinidine) may increase dabigatran levels.
Contraindications/Precautions: Contraindicated in patients with active pathological bleeding. Serious bleeding episodes can occur during therapy. Use caution in patients at risk for bleeding. Use with caution in patients on drugs which increase bleeding (anti-platelet agents, heparin, NSAIDs, and fibrinolytic therapy). Monitor patients for the signs and symptoms of blood loss. PREMATURE DISCONTINUATION OF THERAPY INCREASES THE RISK OF THROMBOTIC EVENTS. MAY CAUSE SPINAL/EPIDURAL HEMATOMA in patients who are receiving neuraxial anesthesia or undergoing spinal puncture. Renal function should be accessed prior to starting therapy and at least yearly in patients over the age of 75 years and in those with CrCL <50 mL/min. Disrupting therapy can increase the risk for stroke. Discontinue use 1-2 days before surgery (CrCL >50 mL/min) or 3-5 days before surgery (CrCL <50 mL/min). Use with caution in the elderly and nursing mothers. Pregnancy Category C.
Adverse Effects: The most common adverse effects are also potentially serious and include bleeding, dyspepsia, nausea, upper abdominal pain, GI hemorrhage, and diarrhea.
Patient Consultation:
May be taken with or without food.
Swallow the capsule whole, do not break, chew or empty the pellets from the capsule.
If a dose is missed, take it as soon as possible. If it is closer to the time of your next dose than the dose you missed, skip the missed dose and return to your dosing schedule. Do not double doses.
Do not discontinue therapy without first consulting physician. You may need to temporarily stop therapy during certain procedures. Be sure to tell all your physicians and your dentist you are currently taking this medication.
Contact a physician if you experience any of the following: unusual bleeding of any kind, pink or brown urine, red or dark stools, coughing or vomiting blood, unusual bruising, unusual pain or swelling, headaches, or dizziness.
Store PRADAXA in its original container. Only remove the dose you are taking and tightly close the container after removing your dose. After opening a bottle of PRADAXA, use within 4 months.
Do not take OTC aspirin, ibuprofen, or naproxen without the knowledge of your physician.
Main Points To Know In Pradaxa Lawsuit
The drug Pradaxa is considered a thrombin inhibitor and is the trade name of dabigatran. When it hit the market in 2010, the manufacturer, Boehringer Ingelheim Pharmaceuticals Inc., one of the world’s biggest pharmaceutical companies, called it to be a safer and more effective drug than the existing thrombin inhibitors.
Doctors prescribed Pradaxa when their patients have atrial fibrillation (AF) that is when patients have arrhythmia, or an irregular heart rhythm, they need to be treated with anticoagulant or an anti-blood-clotting drug. Unfortunately, this popular drug was slowly showing up evidences which were linked to serious side effects or injury that ultimately led to the filing of Pradaxa lawsuit.
Were the patients warned?
So far, the Food and Drug Administration hasn’t issued any recall for Pradaxa. But the Food and Drug Administration (FDA) made strong health warnings to the potential and existing users of the drug saying how that could lead to “serious bleeding events.” A “risk of bleeding” warning is now affixed on the drug's label. The FDA re-examined Pradaxa in November of 2011 as there were raising number of cases and Pradaxa lawsuits.
Some warning signs you should be careful about
Call your doctor or seek immediate medical care if there are any of the following complications:
coughing up or vomiting blood
unexpected pain, swelling, or pain in the joint
unexpected, severe, or uncontrollable bleeding
headaches and dizziness
pink or brown urine
What are the main complications reported?
Patients who take this medicine by injecting it into their spinal and epidural area, are exposed to a higher risk of forming a blood clot which can cause long-term or permanent loss of movement. The risk is higher in patients with:
taking NSAIDs or a medicine to prevent blood clots
epidural catheter
a history of difficult or repeated epidural or spinal punctures
history of problems with spine or spinal surgery
The FDA received reports of 3,781 adverse events and 542 deaths linked with the Pradaxa use in 2011. Being a blood thinner, majority of the adverse reports and deaths were due to excessive bleeding. There were other reports where patients suffered from rectal, brain, and gastrointestinal bleeding. What made it worse is the drug had no known antidote until 2015. Though bleeding caused by Pradaxa can now be treated in some cases with the use of Praxbind, many patients were already harmed and some may still be at the risk of complications.
The updates on lawsuit
More recent Pradaxa lawsuits claim that Boehringer Ingelheim, the manufacturer, continued to provide inadequate warnings about the bleeding risk associated with the drug. Despite the drug company's effort to buy its peace through a large settlement in 2014, Boehringer is still being sued in lawsuit for its alleged failure to warn both the patients and the public about the substantial bleeding risks connected to the drug.
The victis claim Boehringer was negligent by not establishing protocols for doing proper reserach and treating the bleeding episodes. According to the company, the recommended way to cure the condition was through dialysis treatment. But the medical professionals assert it to be an unrealistic and difficult procedure to conduct. the company failed to adequately warn the public of the risks associated and is selling defective drug putting public health at risk.
The victims in the Pradaxa lawsuit can claim for:
Medical costs
Pain and suffering
Lost wages and reduced earning chances
Future medical costs
Wrongful death
Major Side Effects Of Pradaxa You Should Know
Dabigatran, the generic name of the drug, is given mainly to people who have had knee replacement or total hip replacement surgery. It is also prescribed for patients suffering from deep vein thrombosis (DVT, which is a type of blood clot in the major arteries) and pulmonary embolism (blood clot in the lung) so that they don't have the clots forming again.
The reason this medication got popular amongst the physicians as well as the patients is it does not have any strict dietary restriction to go with it. The medicine may be taken with food or on an empty stomach, with water. But as promised by the drug makers, there are some serious side effects of pradaxa which can cause life threatening complications in patients.
The victims of such injuries filed for the lawsuits and are claiming for the financial compensation of all their pain and suffering.
What is the general dose?
Typically, Dabigatran capsules are available in different strengths, such as, 75 mg, 110 mg and 150 mg.
The respective doctor or pharmacist prescribes the patient with the required strength that is right for them. Generally, the dose of dabigatran depends on what it is being used for.
Important safety information
As Pradaxa is available only by prescription, it is the responsibility of the doctor to take into consideration both the risks and benefits of the same. As patient, let your doctor know if you are allergic to any of the active ingredients in the drug to avoid any unnecessary side effects of pradaxa. Also, inform the physician about your medical history, especially of kidney disease, mechanical heart valve, or bleeding problems.
Problems with Pradaxa
the U.S. FDA approved Dabigtran as a new anticoagulant medication which is prescribed to prevent strokes and blood clots in patients with atrial fibrillation. Boehringer Ingelheim Pharmaceuticals, the manufacturer of this drug promoted it to be a better and effective medication than the existing drugs such as warfarin. But within the first three months of the drug’s introduction, there were more than 307 reports with internal bleeding complications, gastrointestinal bleeding, and other related complications. In fact, there have been more than 260 alleged death reports associated with the drug causing from internal bleeding, stroke and hemorrhaging.
Why this happened?
What was initially believed to be a superior anticoagulant and demanded less patient monitoring with little to no change in diet, was unfortunately found to be linked with causing internal bleeding without any reversal agent. The other anticoagulant medications, such as warfarin has been able to counteract internal bleeding complications as they can administer vitamin K.
In fact, Pradaxa’s reversal agent was not approved by the FDA until Oct. 16, 2015, and in these five years hundreds of patients were affected for the utter negligence of the drug makers.
Symptoms of side effects of pradaxa include but not limited to:
· frequent nose bleeds
· bleeding from the gums
· discolored urine
· red or black stools (poop)
· coughing up blood
· vomiting blood
Lawsuits filing claims against Boehringer charge that the company knew of the risks linked with their drug but failed to alert patients of probable complications.
Pradaxa Lawsuit: Complications And Claim
Pradaxa is an anticoagulant manufactured by the German pharmaceutical company Boehringer Ingelheim. It was approved by the FDA in 2010 as a prevention of strokes, but by 2014 there were several death reports linked to the intake of the drug and the company settled 4,000 lawsuits for $650 million.
Pradaxa (dabigatran) helps to prevent platelets in your blood from sticking together and forming a blood clot. Pradaxa is used to reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation. Pradaxa is also used to treat blood clots in the veins of your legs (deep vein thrombosis, or DVT) or lungs (pulmonary embolism, or PE) and reduce the risk of them occurring again.
The drug, however, has caused several complications like gastrointestinal bleeding, kidney bleeding, internal bleeding, pain, brain hemorrhage, hospitalization, suffering and even death. A total of 4,000 pradaxa blood thinner lawsuits have been claimed pointing out the symptoms caused by the drug including several hundred deaths.
The FDA about Pradaxa:
Pradaxa or dabigatran is an anticoagulant or blood thinner that is prescribed to reduce the risk of stroke and blood clots in people with atrial fibrillation. The medicine was approved by the FDA in October 2010. The principal side effects listed at the time of approval were dyspepsia (indigestion) and gastritis (inflammation of the lining of the stomach).
In April 2013, the FDA asked Pradaxa to include a “black box warning” that read a warning “Discontinuing Pradaxa in patients without adequate continuous anticoagulation increases risk of stroke”. Later, the label added “thrombocytopenia (abnormally low number of platelets in the blood)” and “Esophageal ulcers” as two more adverse reactions reported by Pradaxa users.
The FDA’s many required revisions to the Pradaxa label implies that the drug’s original labeling failed to provide adequate warning to patients and physicians about Pradaxa’s many serious and life-threatening complications.
Complications:
Pradaxa is reported to have caused very serious blood clot around the patient’s spinal cord if he has undergone a spinal tap or receive spinal anesthesia (epidural). The risk goes up if the user has a genetic spinal defect, if he has a spinal catheter in place, if he has a history of spinal surgery or repeated spinal taps or if the user is taking other drugs that might affect blood clotting.
The blood clotting might lead to long-term or permanent paralysis. Bleeding is the serious side effect of Pradaxa caused by dabigatran, its most active ingredient. Major or severe bleeding may occur and, regardless of location, may lead to disabling, life-threatening or even fatal outcomes.
Pradaxa lawsuit:
Pradaxa has been linked to thousands of adverse events and over 1,000 fatalities, for which Boehringer Ingelheim has already paid $650 million.
Since its FDA approval in 2010, Pradaxa has been linked to thousands of adverse events and over 1,000 fatalities. These injuries and fatalities resulted in 4,000 lawsuits by August 2012 as filed by Pradaxa patients and consolidated into a multidistrict litigation (MDL).
In May 2014, Boehringer Ingelheim agreed to pay $650 million to settle all of its 4,000 lawsuits. But it wasn’t until October 2015 that the FDA approved an antibody called Praxbind (idarucizumab), which has been shown to reverse the anticoagulation effects of Pradaxa.
That means that for nearly a year and a half, Pradaxa patients did not recover any damages from the drug maker but still had no antidote for the drug’s hemorrhages.
If you or any of the ones you know have suffered from any serious complications and if you didn’t file the pradaxa blood thinner lawsuit during the 2014 settlement, and you took Pradaxa before the antinode hit the market, you are entitled to compensation for the damages caused.
Manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., Pradaxa (dabigatran) is an anticoagulant that was approved by the Food and Drug Administration (FDA) in 2010. It is called a throm…
Patients who suffered serious bleeding events and other health complications after taking Pradaxa can talk to the experts of Pradaxa411 who can help determine if they are eligible for financial compensation. Visit pradaxa411.com/ or 855-228-3953 get a free and confidential evaluation of your case. You may be entitled to compensation for medical expenses, mental anguish and other damages.
New report examines : Pradaxa Market 2017
New report examines : Pradaxa Market 2017
Asia-Pacific Pradaxa market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Request For Full Report @ https://www.reportsandmarkets.com/reports/asia-pacific-pradaxa-market-report-2017-1629090 Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million…
View On WordPress
